Dave Morton Appointed Chief Marketing Officer

Dave Morton joins the STI Technologies Limited team with a rich history in pharmaceutical marketing, leadership and agency experience. Known amongst his peers as a seasoned and innovative marketer, Dave prides himself on a customer-centric, strategic leadership and management approach.

Prior to joining STI in early 2015, Dave spent 14 years in various leadership roles, including EVP managing director at JSA Canada – one of the country’s largest healthcare marketing and communications companies. During his time with JSA, Dave was in charge of many market-leading brands, developing a number of award-winning healthcare professional and direct-to-consumer campaigns at the national level.

“We are excited to welcome Dave to our team and look forward to benefiting from his extensive knowledge and experience,” says Tim Gillis, CEO. “Dave’s background in pharmaceutical marketing and sales combined with his commitment to patient-centric care aligns with our strategic priorities, particularly around specialty, adherence and creating effective programs for our clients across the product lifecycle.”

Dave previously spent 10 years with Rhone Poulenc Rorer (now Sanofi Canada) in various progressive sales and marketing positions.

Residing in Montreal for the last 17 years, Dave and his family are excited to return home to their Atlantic Canadian roots.

MEMOTEXT Corp. and STI Technologies Form Strategic Alliance to Superchange Patient Adherence in Canada

MEMOTEXT Corp. announces today the formation of a strategic alliance with STI Technologies Limited to provide state-of-the art digital communications platform and smart-card technology, to improve patient compliance with medications.

The two Canadian companies are collaborating to integrate their technologies to solve a very costly healthcare problem. Despite operating in different spaces of the healthcare industry, both companies have evidence-based methodologies and validated solutions that complement each other. MEMOTEXT’s JAMA published clinically validated digital adherence solutions have been shown to increase patient adherence by 31.4%. While STI’s recent “STI Reimbursement Programs Correlate with Higher Medication Possession Ratios” discussion paper, demonstrates a 30% relative improvement in medication possession ratio (MPR) over a 12-month period for patients benefiting from a reimbursement solution program. By combining MEMOTEXT’s experience in digital health with STI Technologies’ reimbursement solution technology, the two offer a supercharged adherence program that achieves far greater increases in adherence and MPR than either company could accomplish on its own.

This new partnership will integrate MEMOTEXT’s communications platform and personalized behaviour change messaging, with STI Technologies’ personalized reimbursement solutions. The result is an intervention with far greater increases in adherence and MPR. “We are excited that the findings validate what we’ve been hearing from patients and healthcare professionals for years. Patients highly value these reimbursement programs” says Tim Gillis CEO of STI Technologies “Both STI and MEMOTEXT have a focus on personalized healthcare and a proven track record in improving patient’s adherence and their MPR. It’s exciting to see what we can accomplish in the coming years. By combining our technology, methodologies and offerings into integrated solutions, our partnership will revolutionize patient adherence programs in Canada.”

The alliance brings together STI’s reimbursement support programs, which helps patients with their prescriptions and other healthcare expenses, with MEMOTEXT’s proprietary clinical algorithms and evidence based personalized digital communications. The resulting platform integrates financial assistance for health related services and products with personalized adherence reminders to create a system that delivers validated outcomes, real-time, data-driven, support and behaviour change. The end result is a holistic patient adherence program unlike any other offered in Canada.

“With STI’s expertise in helping patients manage their healthcare expenses and our experience in improving adherence, we complement each other extremely well” said Amos Adler, M.Sc., Founder and President of MEMOTEXT “It’s great that two Canadian digital health companies are collaborating to provide integrated, more affordable, and more effective health interventions. It is a truly exciting time for both of our companies.”